자시오시딘을 포함하는 유방암 억제용 조성물
    21.
    发明公开
    자시오시딘을 포함하는 유방암 억제용 조성물 无效
    含有JACEOSIDIN以抑制乳腺癌的组合物

    公开(公告)号:KR1020060121623A

    公开(公告)日:2006-11-29

    申请号:KR1020050043889

    申请日:2005-05-24

    Abstract: A composition for inhibiting breast cancer comprising jaceosidin is provided to treat breast cancer without toxicity to breast cells by inhibiting activity, infiltration and mobility of matrix metalloproteinase(MMP). The composition for inhibiting breast cancer comprises jaceosidin(5,7,4'-tetramethoxy 6,3'-dimethoxyflavone) represented by the formula(1) as an effective ingredient, wherein the effective concentration of jaceosidin is 10-50 mu M. The composition is the pharmaceutical or food composition.

    Abstract translation: 通过抑制基质金属蛋白酶(MMP)的活性,浸润和迁移性,提供了一种用于抑制乳腺癌的组合物,其包含吉西他赛用于治疗乳腺癌而无毒性的乳腺癌。 用于抑制乳腺癌的组合物包含由式(1)表示的作为有效成分的草甘甜苷(5,7,4'-四甲氧基6,3'-二甲氧基黄酮),其中,有效浓度的麦角苷为10-50μM。 组成是药物或食品组合物。

    셀레노시스테인 또는 셀레노메타이오닌을 포함하는 갭결합을 통한 세포간 정보전달 억제 예방 및 치료용 조성물
    23.
    发明公开
    셀레노시스테인 또는 셀레노메타이오닌을 포함하는 갭결합을 통한 세포간 정보전달 억제 예방 및 치료용 조성물 有权
    用于防止或处理含有SE-(METHYL)SELEOCYSTEINE或SELENO-L-METHIONINE的GAP JUNCTIONAL INTERCELLULAR COMMUNICATION的组合物

    公开(公告)号:KR1020060019264A

    公开(公告)日:2006-03-03

    申请号:KR1020040067841

    申请日:2004-08-27

    Abstract: 본 발명은 셀레노시스테인 또는 셀레노메타이오닌을 포함하는 갭 결합을 통한 세포간 정보전달 억제 예방 및 치료용 조성물에 관한 것이다. 특히 본 발명은 갭 결합을 통한 세포간 정보전달 억제를 방지 및 회복시키며 동시에 세포에 무해한 셀레노시스테인 및 셀레노메타이오닌으로 이루어진 군에서 선택되는 적어도 하나의 셀레노아미노산을 유효성분으로 포함하는 조성물을 제공하며, 상기 조성물은 갭 결합을 통한 세포간 정보전달의 불균형에 의해 발생되는 질환의 예방 및 치료제 용도로 적용할 수 있을 뿐만 아니라, 기존의 약제에 병용사용함으로써 약제의 약리효과를 향상시킬 수 있다.
    셀레노시스테인, 셀레노메타이오닌, 갭 결합을 통한 세포간 정보전달

    유근피 추출물을 포함하는, 갭 결합을 통한 세포간정보전달의 억제 및 항상성의 불균형과 관련된 질환의예방 또는 치료용 조성물
    26.
    发明公开
    유근피 추출물을 포함하는, 갭 결합을 통한 세포간정보전달의 억제 및 항상성의 불균형과 관련된 질환의예방 또는 치료용 조성물 有权
    用于预防和治疗与抑制GAP JUNCTIONAL COMMUNICATION和不平衡的家畜疾病相关的疾病的组合物,包含ULMUS MACROCARPA HANCE EXTRACTINTERNAL CELLULAR

    公开(公告)号:KR1020040060323A

    公开(公告)日:2004-07-06

    申请号:KR1020020087093

    申请日:2002-12-30

    Abstract: PURPOSE: Provided is a composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis, which composition contains Ulmus macrocarpa HANCE extract and effectively recovers the inhibition of gap junctional internal cellular communication and the unbalance of Homeostasis. It is therefore, used for manufacture of medicaments, processed foods, functional foods, beverages and drinks. CONSTITUTION: A composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis is characterized by containing, as an active ingredient, an effective amount of Ulmus macrocarpa HANCE extract or its active fraction, and pharmaceutically acceptable carriers. The extract is obtained by extracting Ulmus macrocarpa HANCE with 60% ethanol solution or hot water.

    Abstract translation: 目的:提供一种预防和治疗与间质连接内部细胞交流抑制和稳态不平衡相关疾病的组合物,该组合物含有榆树枸杞提取物,有效恢复间隙连接内部细胞通讯的抑制和稳态的不平衡。 因此,它用于制造药物,加工食品,功能食品,饮料和饮料。 构成:用于预防和治疗与间质连接内细胞连通抑制和稳态不平衡有关的疾病的组合物,其特征在于,含有有效量的榆树枸杞提取物或其活性成分和药学上可接受的载体作为活性成分。 提取物通过用60%乙醇溶液或热水提取榆树胭脂红获得。

    분비나무 잎 추출물을 포함하는, 갭 결합을 통한 세포간정보전달의 억제 및 항상성의 불균형과 관련된 질환의예방 및 치료용 조성물
    27.
    发明公开
    분비나무 잎 추출물을 포함하는, 갭 결합을 통한 세포간정보전달의 억제 및 항상성의 불균형과 관련된 질환의예방 및 치료용 조성물 失效
    用于预防和治疗与抑制GAP JUNCTIONAL内部细胞通信的疾病相关的疾病的组合物和含有尿囊素叶片提取物的家兔的不平衡

    公开(公告)号:KR1020040060282A

    公开(公告)日:2004-07-06

    申请号:KR1020020087048

    申请日:2002-12-30

    Abstract: PURPOSE: Provided is a composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis, which composition contains Abies nephrolepis leaf extract and effectively recovers the inhibition of gap junctional internal cellular communication and the unbalance of Homeostasis. It is therefore, used for manufacture of medicaments, processed foods, functional foods, beverages and drinks. CONSTITUTION: A composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis is characterized by containing, as an active ingredient, an effective amount of Abies nephrolepis leaf extract, and pharmaceutically acceptable carriers. The extract is obtained by extracting Abies nephrolepis leaf at 80-90 deg.C for 2-3 hours with 60% ethanol solution.

    Abstract translation: 目的:提供一种预防和治疗间质性连接内细胞通讯抑制与稳态不平衡相关疾病的组合物,该组合物含有Abies nephrolepis叶提取物,有效恢复间隙连接内部细胞通讯的抑制和稳态的不平衡。 因此,它用于制造药物,加工食品,功能食品,饮料和饮料。 构成:用于预防和治疗与间质性连接内细胞连通抑制和稳态不平衡有关的疾病的组合物的特征在于,含有有效量的Abies肾盂叶提取物和药学上可接受的载体作为活性成分。 提取物通过在80-90℃下用60%乙醇溶液提取Abies nephrolepis叶片获得2-3小时。

    시스테인 또는 메타이오닌을 포함하는 갭 결합을 통한세포간 정보전달 억제 예방 및 치료용 조성물
    28.
    发明授权
    시스테인 또는 메타이오닌을 포함하는 갭 결합을 통한세포간 정보전달 억제 예방 및 치료용 조성물 有权
    用于预防或治疗含有CYSTEINE或甲硫氨酸的GAP连接细胞间通讯的组合物

    公开(公告)号:KR101217263B1

    公开(公告)日:2012-12-31

    申请号:KR1020040067842

    申请日:2004-08-27

    Abstract: 본발명은시스테인또는메타이오닌을포함하는갭 결합을통한세포간정보전달억제예방및 치료용조성물에관한것이다. 특히본 발명은갭 결합을통한세포간정보전달억제를방지및 회복시키며동시에세포에무해한시스테인및 메타이오닌으로이루어진군에서선택되는적어도하나의아미노산을유효성분으로포함하는조성물을제공하며, 상기조성물은갭 결합을통한세포간정보전달의불균형에의해발생되는질환의예방및 치료제용도로적용할수 있을뿐만아니라, 기존의약제에병용사용함으로써약제의약리효과를향상시킬수 있다.

    RSVL2를 포함하는 MEK1 저해제 및 이를 함유하는항염증 조성물
    29.
    发明公开
    RSVL2를 포함하는 MEK1 저해제 및 이를 함유하는항염증 조성물 失效
    含有RSV2的MEK1抑制剂和含有RSV2的炎性疾病的组合物

    公开(公告)号:KR1020090061187A

    公开(公告)日:2009-06-16

    申请号:KR1020070128088

    申请日:2007-12-11

    Abstract: A MEK1(mitogen-activated protein kinase kinase 1) inhibitor containing RSVL2(3,5,3',4',5'-pentahydroxy-trans-stilbene) is provided to selectively inhibit MEK1 and AP-1(activator protein 1) and treat various inflammatory diseases. A MEK1 inhibitor comprises a RSVL2(3,5,3',4',5'-pentahydroxy-trans-stilbene) of the chemical formula 1 as an active ingredient. A pharmaceutical composition for preventing and treating inflammatory disease comprises 0.01-50 weight% of RSVL2. A pharmaceutical composition further comprises a pharmaceutically allowable carrier, diluents, or excipient. The daily dose of the composition is 0.1-100 mg/kg(weight). A food composition for preventing inflammatory disease comprises 0.001-50 weight% of RSVL2.

    Abstract translation: 提供含有RSVL2(3,5,3',4',5'-五羟基 - 反式 - 二苯乙烯)的MEK1(丝裂原活化蛋白激酶激酶1)抑制剂以选择性抑制MEK1和AP-1(活化蛋白1)和 治疗各种炎性疾病。 MEK1抑制剂包含化学式1的RSVL2(3,5,3',4',5'-五羟基 - 反式 - 二苯乙烯)作为活性成分。 用于预防和治疗炎性疾病的药物组合物包含0.01-50重量%的RSVL2。 药物组合物还包含药学上可允许的载体,稀释剂或赋形剂。 组合物的日剂量为0.1-100mg / kg(重量)。 用于预防炎性疾病的食物组合物包含0.001-50重量%的RSVL2。

    5-데옥시캠페롤을 포함하는 항암제
    30.
    发明公开
    5-데옥시캠페롤을 포함하는 항암제 有权
    含有5-脱氧皮质醇的反应剂

    公开(公告)号:KR1020090061186A

    公开(公告)日:2009-06-16

    申请号:KR1020070128087

    申请日:2007-12-11

    Abstract: An anticancer composition containing a 5-deoxykaempferol is provided to inhibit the activation of matrix metalloproteinase(MMP) and the infiltration of cancer cell. An anticancer composition of 0.1-50 weight% of 5-deoxykaempferol of the chemical formula 1 an active ingredient. The anticancer comprise medicine, food, food additive, beverage, or beverage additive. The cancer is colon cancer, stomach cancer, breast cancer, and liver cancer. The anticancer composition further comprises a pharmaceutically allowable carrier, diluents, or excipient. The daily dose of anticancer composition is 0.1-100 mg/kg(body weight).

    Abstract translation: 提供含有5-deoxykaempferol的抗癌组合物以抑制基质金属蛋白酶(MMP)的激活和癌细胞的浸润。 抗化学组合物为0.1-50重量%的化学式1的5-脱氧ka酚酯为活性成分。 抗癌剂包括药物,食品,食品添加剂,饮料或饮料添加剂。 癌症是结肠癌,胃癌,乳腺癌和肝癌。 抗癌组合物还包含药学上可允许的载体,稀释剂或赋形剂。 抗癌组合物的日剂量为0.1-100mg / kg(体重)。

Patent Agency Ranking